Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications

被引：9

作者：

Borad, M. ^{[1
]}

Javle, M. ^{[2
]}

Shaib, W. L. ^{[3
]}

Mody, K. ^{[4
]}

Bergamo, F. ^{[5
]}

Harris, W. P. ^{[6
]}

Damjanov, N. ^{[7
]}

Macarulla, T. ^{[8
]}

Brandi, G. ^{[9
]}

Masi, G. ^{[10
]}

Busset, M. Droz Dit ^{[11
]}

Boncompagni, A. ^{[12
]}

Dimova-Dobreva, M. ^{[12
]}

Engelhardt, M. ^{[12
]}

Saulay, M. ^{[12
]}

Halfdanarson, T. R. ^{[13
]}

Knox, J. ^{[14
]}

Abou-Alfa, G. K. ^{[15
]}

Personeni, N. ^{[16
]}

Mazzaferro, V. ^{[17
]}

机构：

[1] Mayo Clin Canc Ctr, Dept Oncol, Scottsdale, AZ USA

[2] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

[3] Emory Univ, Hematol & Oncol, Atlanta, GA USA

[4] Mayo Clin, Hematol & Oncol, Jacksonville, FL USA

[5] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol 1, Padua, Italy

[6] Univ Washington, Med, Med Ctr, Seattle, WA USA

[7] Univ Penn, Abramson Canc Ctr, Hematol & Oncol, Philadelphia, PA USA

[8] Vall Hebron Inst Oncol, Med Oncol, VHIO Cellex Ctr, Barcelona, Spain

[9] Univ Bologna, Med Oncol, IRCCS Azienda Osped, Bologna, Italy

[10] AOU Pisana Stabilimento Santa Chiara, Oncol Med, Pisa, Italy

[11] Fdn IRCCS, Hepatopancreatobiliary & Digest Surg, Ist Nazl Tumori Milano, Milan, Italy

[12] Basilea Pharmaceut Ltd, Dept Dev, Basel, Switzerland

[13] Mayo Clin, Dept Med Oncol, Rochester, NY USA

[14] Princess Margaret Canc Ctr, Oncol Med, Toronto, ON, Canada

[15] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[16] Ist Clin Humanitas, Dept Oncol & Hematol, Rozzano, Italy

[17] Fdn IRCCS, Oncol Med, Ist Nazl Tumori Milano, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

59P

引用

页码：S567 / S568

页数：2

共 50 条

[31] Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis
Javle, M.
Sadeghi, S.
Roychowdhury, S.
El-Khoueiry, A.
Goyal, L.
Philip, P.
Kelley, R.
Borbath, I.
Macarulla, T.
Yong, W.
Tanasanvimon, S.
Li, A.
Howland, M.
Pande, A.
Abou-Alfa, G.
ANNALS OF ONCOLOGY, 2020, 31 : S219 - S219
[32] A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
Zhang, Lei
Zheng, Hao
Xu, Linyu
You, Si
Shen, Yuanyuan
Han, Yang
Anderson, Steve
DIAGNOSTICS, 2023, 13 (12)
[33] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Valle, Juan W.
Morizane, Chigusa
Karasic, Thomas Benjamin
Furuse, Junji
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[34] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma (vol 51, pg 911, 2021)
Tsujie, Masanori
Iwai, Tomohisa
Kubo, Shoji
Ura, Takashi
Hatano, Etsuro
Sakai, Daisuke
Takeda, Yutaka
Kaibori, Masaki
Kobayashi, Tomoe
Katanuma, Akio
Katayose, Yu
Fukase, Koji
Sakurai, Naoki
Ito, Yukiko
Sato, Fumiya
Maeda, Atsuyuki
Asada, Masanori
Morizane, Chigusa
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (11) : 1694 - 1694
[35] Cholangiocarcinoma patients with FGFR2 fusions/ rearrangements but primary refractory to pemigatinib: the real challenge?
Rizzo, A.
Ricci, A. D.
Brandi, G.
ESMO OPEN, 2024, 9 (10)
[36] Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.
Shroff, Rachna T.
Avogadri, Francesca
Weng, Richard
Li, Ai
Dambkowski, Carl L.
Lamarca, Angela
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[37] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Goyal, Lipika
Saha, Supriya K.
Liu, Leah Y.
Siravegna, Giulia
Leshchiner, Ignaty
Ahronian, Leanne G.
Lennerz, Jochen K.
Vu, Phuong
Deshpande, Vikram
Kambadakone, Avinash
Mussolin, Benedetta
Reyes, Stephanie
Henderson, Laura
Sun, Jiaoyuan Elisabeth
Van Seventer, Emily E.
Gurski, Joseph M., Jr.
Baltschukat, Sabrina
Schacher-Engstler, Barbara
Barys, Louise
Stamm, Christelle
Furet, Pascal
Ryan, David P.
Stone, James R.
Iafrate, A. John
Getz, Gad
Porta, Diana Graus
Tiedt, Ralph
Bardelli, Alberto
Juric, Dejan
Corcoran, Ryan B.
Bardeesy, Nabeel
Zhu, Andrew X.
CANCER DISCOVERY, 2017, 7 (03) : 252 - 263
[38] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
Goyal, Lipika
Saha, Supriya K.
Liu, Leah Y.
Siravegna, Giulia
Leshchiner, Ignaty
Ahronian, Leanne G.
Lennerz, Jochen K.
Phuong Vu
Mussolin, Benedetta
Reyes, Stephanie
Furet, Pascal
Iafrate, A. John
Getz, Gad
Porta, Diana G.
Tiedt, Ralph
Bardelli, Alberto
Juric, Dejan
Corcoran, Ryan B.
Bardeesy, Nabeel
Zhu, Andrew X.
CANCER RESEARCH, 2017, 77
[39] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Giovanni Brandi
Valeria Relli
Marzia Deserti
Andrea Palloni
Valentina Indio
Annalisa Astolfi
Salvatore Serravalle
Alessandro Mattiaccio
Francesco Vasuri
Deborah Malvi
Chiara Deiana
Maria Abbondanza Pantaleo
Matteo Cescon
Alessandro Rizzo
Masaru Katoh
Simona Tavolari
Scientific Reports, 14
[40] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Brandi, Giovanni
Relli, Valeria
Deserti, Marzia
Palloni, Andrea
Indio, Valentina
Astolfi, Annalisa
Serravalle, Salvatore
Mattiaccio, Alessandro
Vasuri, Francesco
Malvi, Deborah
Deiana, Chiara
Pantaleo, Maria Abbondanza
Cescon, Matteo
Rizzo, Alessandro
Katoh, Masaru
Tavolari, Simona
SCIENTIFIC REPORTS, 2024, 14 (01)

← 1 2 3 4 5 →